Clinical trial · Interventional
Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）
A Phase II, Second-line, Single-arm Clinical Trial of Carelizumab Combined With Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
NCT04806243CI-TRIAL-00052495unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To investigate the efficacy and safety of carelizumab combined with regorafenib in second-line treatment for patients with primary hepatocellular carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Regorafenib Pill&Camrelizumab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Carelizumab Combined With Regorafenib arm
- interventionNames
- Drug: Regorafenib Pill&Camrelizumab
Primary outcomes (1)
- measure
- os（overall survival）
- timeFrame
- 21 days
- description
- overall survival
Secondary outcomes (5)
- measure
- PFS（progression-free survival）
- timeFrame
- 21 days
- description
- progression-free survival
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Not convenient to disclose Exclusion Criteria: * Not convenient to disclose
References
Publications (0)
Data not yet available
No reference posted for this study.